LIMN

Liminatus Pharma, Inc. Class A Common Stock | Healthcare

2.97974%

Analisi Pre-Earnings (Antonio AI)

2025-12-18
Sentiment
55.0/100
Salute

Weak

Verdict

A pharma company chasing crypto hype with zero available financial data. ⚠️ This looks less like a biotech play and more like a shell game. I wouldn't touch this thing. 📉

Catalysts
  • Potential finalization of the $30M equity investment MOU, which could provide a temporary pop for bagholders.
Rischi
  • Complete lack of a coherent business strategy.
  • Zero financial transparency makes it impossible to assess cash burn or solvency.
Approfondisci con Antonio
Valutazione
P/E (TTM)-6.975416931374104
Forward P/E-6.975416931374104
P/S0.0
Market Cap23383843
Finanze & Debito
CashNone
DebtNone
Debt/Equity-0.8764931524162349
Current Ratio0.4200841096798044
Redditività
ROE0.3918279704851829
Profit Margin0.0
Operating Margin0.0
Rev. Growth0.0
Ultime News (Context per AI)